These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29904126)

  • 21. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
    Recker RR; Benson CT; Matsumoto T; Bolognese MA; Robins DA; Alam J; Chiang AY; Hu L; Krege JH; Sowa H; Mitlak BH; Myers SL
    J Bone Miner Res; 2015 Feb; 30(2):216-24. PubMed ID: 25196993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative effect of serotonin-norepinephrine reuptake inhibitor therapy on rat bone tissue after orchidectomy.
    Fekete S; Simko J; Mzik M; Karesova I; Zivna H; Zivny P; Pavliková L; Palicka V
    Eur J Pharmacol; 2015 Aug; 761():65-9. PubMed ID: 25934570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial.
    Gianatti EJ; Dupuis P; Hoermann R; Strauss BJ; Wentworth JM; Zajac JD; Grossmann M
    Diabetes Care; 2014 Aug; 37(8):2098-107. PubMed ID: 24804695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
    Amory JK; Watts NB; Easley KA; Sutton PR; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
    J Clin Endocrinol Metab; 2004 Feb; 89(2):503-10. PubMed ID: 14764753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.
    Glorieux FH; Devogelaer JP; Durigova M; Goemaere S; Hemsley S; Jakob F; Junker U; Ruckle J; Seefried L; Winkle PJ
    J Bone Miner Res; 2017 Jul; 32(7):1496-1504. PubMed ID: 28370407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial.
    Gianatti EJ; Dupuis P; Hoermann R; Zajac JD; Grossmann M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3821-8. PubMed ID: 24978674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
    Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
    J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI).
    Van Caenegem E; Wierckx K; Taes Y; Schreiner T; Vandewalle S; Toye K; Lapauw B; Kaufman JM; T'Sjoen G
    Eur J Endocrinol; 2015 Feb; 172(2):163-71. PubMed ID: 25550352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone mineral density and serum testosterone in chronically trained, high mileage 40-55 year old male runners.
    MacKelvie KJ; Taunton JE; McKay HA; Khan KM
    Br J Sports Med; 2000 Aug; 34(4):273-8. PubMed ID: 10953900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
    Välimäki MJ; Salmela PI; Salmi J; Viikari J; Kataja M; Turunen H; Soppi E
    Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.
    Negredo E; Diez-Pérez A; Bonjoch A; Domingo P; Pérez-Álvarez N; Gutierrez M; Mateo G; Puig J; Echeverría P; Escrig R; Clotet B
    J Antimicrob Chemother; 2015 Jul; 70(7):2104-7. PubMed ID: 25769303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of testosterone treatment on bone mineral density in men over 65 years of age.
    Snyder PJ; Peachey H; Hannoush P; Berlin JA; Loh L; Holmes JH; Dlewati A; Staley J; Santanna J; Kapoor SC; Attie MF; Haddad JG; Strom BL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1966-72. PubMed ID: 10372695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men.
    Aminorroaya A; Kelleher S; Conway AJ; Ly LP; Handelsman DJ
    Eur J Endocrinol; 2005 Jun; 152(6):881-6. PubMed ID: 15941928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.
    Guo CY; Jones TH; Eastell R
    J Clin Endocrinol Metab; 1997 Feb; 82(2):658-65. PubMed ID: 9024272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.
    Emmelot-Vonk MH; Verhaar HJ; Nakhai Pour HR; Aleman A; Lock TM; Bosch JL; Grobbee DE; van der Schouw YT
    JAMA; 2008 Jan; 299(1):39-52. PubMed ID: 18167405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.
    Sinclair M; Grossmann M; Hoermann R; Angus PW; Gow PJ
    J Hepatol; 2016 Nov; 65(5):906-913. PubMed ID: 27312945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome.
    Rodriguez-Tolrà J; Torremadé J; di Gregorio S; Del Rio L; Franco E
    Andrology; 2013 Jul; 1(4):570-5. PubMed ID: 23686863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.